WO2001051051A2 - AGENTS, SUCH AS NICOTINAMIDE OR cADPR FOR THE TREATMENT OF SKIN DISORDERS - Google Patents
AGENTS, SUCH AS NICOTINAMIDE OR cADPR FOR THE TREATMENT OF SKIN DISORDERS Download PDFInfo
- Publication number
- WO2001051051A2 WO2001051051A2 PCT/IL2001/000017 IL0100017W WO0151051A2 WO 2001051051 A2 WO2001051051 A2 WO 2001051051A2 IL 0100017 W IL0100017 W IL 0100017W WO 0151051 A2 WO0151051 A2 WO 0151051A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- cells
- metabolite
- treatment
- cadpr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention is generally concerned with compositions for the treatment of hyperproliferative diseases as well as for the treatment of aging of the epidermis, for use of agents for the preparation of said pharmaceutical
- compositions as well as for methods of treatment of hyperproliferative diseases and aging of the epidermis.
- regulating factors including Vitamin D3, Vitamin A, a number of cytokines and ⁇ o growth factors, as well as extra- and intracellular free Ca " .
- Skin benign and malignant hyperproliferative disorders arise from faulty regulation of growth and differentiation of epidermal cells.
- the faulty regulation may be due to lack of response or lack of appropriate response to regulating factors, or due to non-normal levels or function of the regulating factors themselves. For example, it is well
- NA nicotinamide
- NA is known as a weak free-radical scavenger, inhibitor of poly-ADP-ribose synthetase and inducible nitric oxide synthase in pancreatic isiets( ⁇ ).
- NA is known as a weak free-radical scavenger, inhibitor of poly-ADP-ribose synthetase and inducible nitric oxide synthase in pancreatic isiets( ⁇ ).
- S peroxide-induced depIetion
- cADPR cyclic ADP ribose
- a metabolite induces activation of cADPribose synthesis in renal LLC-PK
- atRA the effect of atRA on cADPR synthesis in human keratinocytes was not studied.
- the present invention is based on the surprising finding that nicotinamide (NA) as well as cyclic adenosine diphosphate-ribose (cADPR) can promote differentiation, and inhibit proliferation of human epidermal cells in two model systems: a spontaneously immortalized human keratinocyte, termed: "HaCat cell lines " which can be used as a model for highly proliferative epidermis, e.g. psoriatic epidermis (9) ; and for effects of external modulators of epidermal differentiation 0 ()) : and an epidermal carcinoma cell line termed: "A431 " bearing the mutated alleles of p53. which serves as a model for the testing of anti-cancerogenic drugs .
- NA nicotinamide
- cADPR cyclic adenosine diphosphate-ribose
- the present invention is further based on the surprising finding that a composition comprising a mixture of NA and a metabolite of Vitamin D3, being the l ⁇ ,25 dihydroxy-vitamin D3 (termed hereinafter: "7co, 25 (OH) 2 D3”), is more effective in promoting differentiation and inhibiting proliferation, than the sum of each of the individual effects of NA and the vitamin D3 metabolite when administered separately.
- a composition comprising a mixture of NA and a metabolite of Vitamin D3, being the l ⁇ ,25 dihydroxy-vitamin D3 (termed hereinafter: "7co, 25 (OH) 2 D3"
- 7co, 25 (OH) 2 D3 l ⁇ ,25 dihydroxy-vitamin D3
- the present invention is further based on the surprising finding that a composition comprising a mixture of all-trans-retinoic acid (atRA), (which is a metabolite of vitamin A), together with NA is more effective in promoting differentiation and inhibiting proliferation of human epidermal cells, than the sum of the effects of each of these compounds separately, i.e. NA and atRA have a synergistic effect in promoting differentiation and inhibiting proliferation of human epidermal cells.
- atRA all-trans-retinoic acid
- the present invention is further based on surprising findings that long-term NA- treated human keratinocytes are high resistant to hydrogen peroxide-induced oxidative stress, thus indicating that NA may serves as strong antioxidant and therefore a potential anti- aging and anti-cancer protector of human epidermal cells.
- the present invention provides a composition for the treatment of hyperproliferative epidermal diseases, and for aging of epidermis comprising a carrier and as an active ingredient or agent selected from the group consisting; of: (i) nicotinamide (NA);
- cADPR cyclic adencsine diphosphate-ribose
- T he composition may be pharmaceutical or cosmetic.
- he composition of the present invention is intended for topical as well as for subcutaneous administrations together with a dermatology or cosmetically acceptable carrier and may be in the form of cream, solution, salve, lotion, ointment or fatty ointment.
- the composition may be used to increase the anti-oxidative properties of epidermal cells, for example as an anti-cancer or anti-aging composition.
- the cosmetic composition of the invention When used for the treatment of aging epidermis, the cosmetic composition of the invention may be administered as any state of the art cosmetic preparation together with a cosmetically acceptable carrier.
- the concentration of nicotinamide in the pharmaceutical composition of the invention should be from about 0.5 mM to about 20 mM; preferably from about I mM to about 10 mM; most preferably from about 2.5 mM to about 5 mM.
- the concentration of the cADPR in the composition of the invention should be from about 1 ⁇ M to about 100 ⁇ M; preferably from about 10 ⁇ M to about 50 ⁇ M; most preferably from about 25 ⁇ M to about 50 ⁇ M.
- the composition comprises a combination of NA and cADPR the ratio between the two should be from about
- the composition of the invention comprises a mixture of NA and Vitamin D3 metabolite.
- the vitamin D3 metabolite is i ⁇ .25 dihydroxy-vitamin D 3 .
- the concentration of the NA in the mixture should be within the ranges as defined above.
- the ratio between the NA and the D3 should be from about 5000: 1 to about 500,000: 1 wherein the final concentration of the metabolite vitamin D3 should be from about 0.01 ⁇ M to about 1 ⁇ M.
- Other suitable metabolites of vitamin D3 can be 25-hydroxycholecalciferol (25 OH D3); and 24R. 25-dihydroxycholecalciferol (24R, 25(OH) 2 D3).
- the present invention concerns a composition
- a composition comprising NA in the range of concentrations as defined above and a metabolite of vitamin A. preferably by atRA.
- the final concentration of atRA should be from about 0.1 nM to about 10 nM.
- the ratio between NA and atRA should be from about to about 5 x 10 * : 1 to about 25 x 10 :1.
- hyperproliferative epidermal diseases refers to diseases which arc characterized by a higher than normal level of proliferation of epidermal cells, and. as a rule, also by abnormal differentiation.
- the hyperproliferative epidermal diseases may be malignant: and examples of such malignant diseases are squamous-cell carcinoma (SCC), basal-cell carcinoma (BCC) and other non-melanoma skin cancers (NMSCs).
- SCC squamous-cell carcinoma
- BCC basal-cell carcinoma
- NMSCs non-melanoma skin cancers
- the hyperproliferative diseases may be benign diseases such as for example: psoriasis, common warts, keratoacanthoma, seborrhoic keratosis as well as other benign skin disorders like seborrhea or ichthyosis.
- aging of epidermis refers to all symptoms associated with physiological aging such as wrinkles, loss of elasticity, decreased metabolism, dryness. roughness, burning and atrophy of skin, itching, heperpilosity and alopecia.
- treatment refers either to alleviation of the adverse effects of the disease, which alleviation may be manifested, for example, by decrease in the rate of proliferation, improved differentiation, or combination of the two: by complete elimination of the non-normal proliferation and differentiation of the epidermal cells in the diseased person, or alternatively by prevention of the non-normal differentiation and/or higher than normal proliferation before they have occurred.
- Treatment in the cosmetic aspect may include also prevention of aging signs before they occur.
- the compounds of the invention may be used as anti-aging and anti-cancer compositions.
- the present invention concerns use of an agent selected from the group consisting of: (i) nicotinamide (NA)
- the present invention concerns a method for the treatment of hyperproliferative epidermal diseases or for the treatment of aging of the epidermis comprising: applying to the skin of an individual in need of such treatment, a therapeutically effective amount of an agent selected from the group consisting of: (i) nicotinamide (NA);
- cADPR cyclic adenosine diphosphate-ribose
- the amount is an amount which can decrease, to a measurable amount, the proliferation of the cells as indicated by measurement of the activity of mitochondrial dehydrogenase enzymes of living cells (MTT assay)' ' and by counting of basal cells level .
- nicotinamide N A
- cADPR cyclic adenosine diphosphate-ribose
- the cells may be malignant epidermal cells such from squamous cell carcinoma (SCC) basal cell carcinoma (BCC) or other non-melanoma skin cancers (NMSC's) or alternatively may be hyperproliferative benign cells, such as human keratiocytes from psoriatic skin, and keratinocytes from keratoacanthoma, common warts or seborrhoic keratoses lesions.
- SCC squamous cell carcinoma
- BCC basal cell carcinoma
- NMSC's non-melanoma skin cancers
- hyperproliferative benign cells such as human keratiocytes from psoriatic skin, and keratinocytes from keratoacanthoma, common warts or seborrhoic keratoses lesions.
- the cells may also be from other benign skin disorders such as ichthyosis.
- the cells may also be epidermal cells with symptoms of skin ageing (dryness, roughness, burning and atrophy of the skin, itching, cold intolerance, wrinkles, heperpiiosity, alopecia), when the epidermal cells are involved in natural, or oxidative stress-inducing aging process.
- cells may be skin cells having increasing sensitivity to oxidative injury (cells with predisposition to initiation of tumors).
- the invention further concerns a method for increasing the anti-oxidative properties of epidermal cells comprising contacting the cells with an effective amount of NA.
- Fig. 1A shows the effect of NA on HaCat and A431 cell proliferation
- Fig. IB shows anti-proliferative effect of NA on cultured human epide ⁇ nal keratinocytes
- Fig. 2 shows the effect of D3 metabolite (l ⁇ 25(OH) 2 D3) on HaCat and
- Fig. 3 shows the effect of cADPR on HaCat and A431 cell proliferation
- Fig. 4 shows the effect of Vitamin A metabolite (atRA) on HaCat and A431 cell proliferation
- Fig. 5A shows the effect of a combination of NA and D3 metabolite (l ⁇ 25(OH) 2 D3) on HaCat cell line proliferation;
- Fig. 5B shows the combined effect of NA and D3 metabolite (l ⁇ 25(OH) 2 D3) on HaCat cell lines proliferation minus the effect of each of these compounds separately (synergism);
- Fig. 6A shows the effect of a combination of NA and D3 metabolite (l ⁇ 25(OH) 2 D3) o ⁇ A431 cell line proliferation;
- Fig. 6B shows the combined effect of NA and D3 metabolite (l ⁇ 25(OH)2D3) on A431 cell lines proliferation minus the effect of each of these compounds separately (synergism);
- Fig. 7 A shows the effect of a combination of NA and cADPR on HaCat cell line proliferation
- Fig. 7B shows the combined effect of NA and cADPR on HaCat cell lines proliferation minus the effect of each of these compounds separately (synergism);
- Fig. 8 A shows the effect of a combination of NA and cADPR on A431 cell line proliferation;
- Fig. 8B shows the combined effect of NA and cADPR on A431 cell lines proliferation minus the effect of each of these compounds separately (synergism);
- Fig. 9 A shows the effect of a combination of NA and Vitamin A metabolite (atRA) on HaCat cell line proliferation
- Fig. 9B shows the combined effect of NA and Vitamin A metabolite (atRA) on HaCat cell lines proliferation minus the effect of each of these compounds separately (synergism);
- Fig. 10A shows the effect of a combination of NA and Vitamin A metabolite (atRA) on A431 cell line proliferation
- Fig. 10B shows the combined effect of NA and Vitamin A metabolite (atRA) on A431 cell lines proliferation minus the effect of each of these compounds separately (synergism);
- Fig. 11 shows the effect of NA on involucrin and keratin klO expression in HaCat cells
- Fig. 12 shows the effect of NA on basal and envelope cornified cell expression in HaCat cell line
- Fig. 13 shows the effect of NA on apoptosis level in HaCat and A431 cell lines: and Fig. 14 shows the resistance of HaCat cells treated for long-term period with
- the immortalized human keratinocyte HaCat cells were routinely cultured in 75 cm " (Tasks using Eagle's minimal essential medium (MED-EAGLE) supplemented with 5% fetal calf serum (FCS) and 1% of antibiotics (penicillin 20 u/ml; streptomycin 20 ⁇ g/ml and nystatin 2.5 u/ml) at 37°C in 95% air/5% C0 2 . Medium was changed every 3-4 days. In some experiments HaCat cells cultivated for 6 months in routinely used medium supplemented with 10 mM NA or 20 mM NA (long-term culture of HaCat cells with NA) were used.
- MED-EAGLE Eagle's minimal essential medium
- FCS fetal calf serum
- antibiotics penicillin 20 u/ml
- MEM-EAGLE Eagle's minimal essential medium
- FCS fetal calf serum
- PBS Dulbecco ' s phosphate buffered saline
- trypsin 0.05%-EDTA solution (1 :000) w ere obtained from Biological Industries (Israel). Keratinocyte Growth Medium ® -2 Bullet Kit” CC-3107 (for accelerated proliferation) was received from BioWhittaker, Inc. A Cambrex Company, Clonetics, USA).
- Anti-human cytokeratin 10 (NCL-CK10) and involucrin (NCL-INV) mouse monoclonal antibodies were obtained from Novocastra Laboratories Ltd.
- HaCat and A43 1 cells were propagated in 25 cm " or 75 cm tissue culture flasks (Corning, USA) and 24- well and 96-well tissue culture plates (Corning, USA) were used for incubation of the cells with different doses of NA (1-50 mM/I), cADPR (1-50 microM), Vitamin D3 (1- 10000 nM) and atRA (0.1-10000 nM).
- Cornified cell envelope fo ⁇ nation was dete ⁇ nined (Sun T-T, Green, H: Differentiation of the epide ⁇ nal keratinocytes in cell culture: fo ⁇ nation of cornified envelope, Cell, 9:511-521, 1976 as a measure of late differentiation processes in HaCat cells treated with nicotinamide. Briefly, cells were seeded in 24-well tissue culture plates and after attachment (24 h) exposed to various concentrations of NA (0, 4. 10. 1 5 and 20 mM) for 96 h. The cells were detached and resuspended in medium. Counting of total and basal (small, rounded) cells was performed using hemocytometer in tetraplicate aliquotes.
- Involucrin expression was detected by antihuman involucrin mouse monoclonal antibody ir final dilution 1/100. After blocking the cells were incubated with the aforementioned antibodies at 37°C for 1 h in a humidified chamber. Exhaustive washed with PBS cells were incubated with CyTM 2-conjugated goat anti-mouse IgG in final dilution 1/50 for 30 min. at room temperature. Slides were viewed under Zeiss microscope (Axioskop-2) equipped with epifluorescence optics and the appropriate filters to avoid cross-channel contamination. Level of keratin 10 and involucrin expression was estimated by counting the positive cells relative to the total cell number. In each slide at least 500- 1000 cells were scored. The data presents mean of 3 independent experiments.
- HaCat and A431 cells were seeded in 25 cm tissue culture flasks and incubated for 72 h with 0, 5, 10 and 20 mM of NA. Cells treated with 5% ethanol served as positive control of apoptosis.
- the nuclei for flow cytometry analysis of DNA were prepared by a detergent trypsin method with propidium iodide (Lars L Rindelov: A detergent trypsin method for the preparation of nuclei for FACS DNA anlaysis, Cytometry 3(5)323-327, 1983). Briefly, the cells (10 per tube) were washed with PBS.
- the cell pellet was resuspended in 40 ⁇ l citrate buffer (pH 7.6) supplemented with 250 mM sucrose, 40 mM trisodium citrate and 5% DMSO. Then resuspended cells were incubated in 450 ⁇ l solution with trypsin (0.15 mg/ml, pH 7.6) for 10 minutes. Following next 10 min. incubation with trypsin inhibitor and ribonuclease A the fluorochrome solution containing propidium iodide 100 ⁇ g/ml was added to nuclei. The tubes were placed in the dark before flow cytometry analysis.
- Flow cytometry analysis was carried out in fluorescence-activated cell sorter (FACScan; Becton Dickinson, CA) and level of apoptosis was determined using the Cell Quest Program of Becton Dickonson. Each experiment was repeated three times.
- Results are presented as mean ⁇ standard deviation of the mean (mean ⁇ SD). Statistical significance (PO.05) was derived by Student's t-test.
- Epidermal Keratinocytes and 5x10 /ml squamous carcinoma A431 cells were incubated with varying amounts of NA for a period of 72 hours.
- the proliferation was estimated by the MTT method, as described in Section C of Experimental Procedures, and was expressed as the percent from control (untreated cells).
- the results are shown in Fig. 1A and IB, which indicates that both HaCat,
- A43 1 and Cultured Human Epidermal Keratinocyte cell proliferation was significantly inhibited by NA.
- Vitamin D3 metabolite l ⁇ 25(OH) 2 D3
- Vitamin A metabolite atRA
- Example 3 Synergistic effects of NA and a Vitamin D3 metabolite HaCat cells and A431 cells were incubated with the D3 metabolite separately, and the D3 metabolite together with NA (Figs. 5A and 6A, respectively) for a period of 72 hours.
- the combined effect of NA and D3 metabolite was higher than the summation of each of these effects separately, in an amount of above 12% for a concentration of 100 nM of D3 and 5 mM NA in respect of HaCat cells, and i o above 20% synergism for 10 nM of D3 metabolite and 5 mM NA for A431 cells.
- cADPR and 5 mM of NA showed a synergistic effect of above 20%) in inhibiting proliferation as compared to the effect of each of these agents in that concentration alone in respect of HaCat cells, and 0 25 ⁇ M of cADPR and 2.5 mM NA showed a synergism of above 16%> in inhibiting proliferation of A431 cells, as compared to the inhibition of each of these components alone.
- HaCat cells and A431 cells were incubated with NA at an amount of 5 mM and 2.5 mM respectively and varying concentrations of atRA (0.1 nM-1 ⁇ M) and the results are shown in Figs. 9 and 10, respectively.
- the effect of the combination showed a synergism of above 25%o at a concentration of 0.1 ⁇ M atRA for A431 cell (Fig. 10B) and a synergism of above 20%) for a concentration of 10 ⁇ M of atRA (for HaCat cells) (Fig. 9B), above the effect achieved for each of the separate agents Vitamin A and NA in the same amounts separately.
- NA treatment simulated both expression of keratin 10
- K10 involucrin which are markers of early and late differentiation processes of the epidermal cells.
- NA also changed the ratio between the amount of cells, and envelope cornified cells, so that a higher proportion of cells tested were enveloped cornified cells, which are more differentiated cells, as can be seen in Fig. 12.
- Fig. 13 shows that NA becomes cytotoxic to cell as determined by the level of apoptosis in amounts of 30 mM for A431 cells and 50 mM for HaCat cells. This means that the effect of NA on cell proliferation, as for example, expressed in Fig. 1 is manifested in concentration of NA which are below the concentrations toxic to cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01900231A EP1259240B8 (en) | 2000-01-11 | 2001-01-09 | Agents, such as nicotinamide or cadpr for the treatment of skin disorders |
CA2396186A CA2396186C (en) | 2000-01-11 | 2001-01-09 | Agents for the treatment of skin disorders |
AU23929/01A AU782558B2 (en) | 2000-01-11 | 2001-01-09 | Agents, such as nicotinamide or cADPR for the treatment of skin disorders |
IL15070601A IL150706A0 (en) | 2000-01-11 | 2001-01-09 | Composition and methods for the treatment of skin disorders |
DE60121303T DE60121303T2 (en) | 2000-01-11 | 2001-01-09 | MEDIUM, SUCH AS NICOTINAMIDE OR CADPR FOR TREATMENT OF SKIN DISEASES |
US10/192,842 US20030032617A1 (en) | 2000-01-11 | 2002-07-11 | Composition and methods for the treatment of skin disorders |
IL150706A IL150706A (en) | 2001-01-09 | 2002-07-11 | Combinations of nicotinamide and vitamin d agents and use thereof in preparation of compositions for the treatment of skin disorders |
HK03103749A HK1051497A1 (en) | 2000-01-11 | 2003-05-27 | Agents, such as nicotinamide or cadpr for the treatment of skin disorders |
US12/242,243 US20090098065A1 (en) | 2000-01-11 | 2008-09-30 | Composition and methods for the treatment of skin disorders |
US15/097,938 US20160220589A1 (en) | 2000-01-11 | 2016-04-13 | Compositions and methods for the treatment of skin disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL133976 | 2000-01-11 | ||
IL133976A IL133976A (en) | 2000-01-11 | 2000-01-11 | Agents for the treatment of skin disorders |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2006/000552 Continuation-In-Part WO2006120681A2 (en) | 2000-01-11 | 2006-05-10 | Compositions and methods for skin care |
US91409308A Continuation-In-Part | 2000-01-11 | 2008-06-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/192,842 Continuation-In-Part US20030032617A1 (en) | 2000-01-11 | 2002-07-11 | Composition and methods for the treatment of skin disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001051051A2 true WO2001051051A2 (en) | 2001-07-19 |
WO2001051051A3 WO2001051051A3 (en) | 2002-06-27 |
WO2001051051B1 WO2001051051B1 (en) | 2002-09-26 |
Family
ID=11073692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2001/000017 WO2001051051A2 (en) | 2000-01-11 | 2001-01-09 | AGENTS, SUCH AS NICOTINAMIDE OR cADPR FOR THE TREATMENT OF SKIN DISORDERS |
Country Status (11)
Country | Link |
---|---|
US (1) | US20030032617A1 (en) |
EP (1) | EP1259240B8 (en) |
AT (1) | ATE332136T1 (en) |
AU (1) | AU782558B2 (en) |
CA (1) | CA2396186C (en) |
DE (1) | DE60121303T2 (en) |
DK (1) | DK1259240T3 (en) |
ES (1) | ES2267706T3 (en) |
HK (1) | HK1051497A1 (en) |
IL (2) | IL133976A (en) |
WO (1) | WO2001051051A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005078091A1 (en) * | 2004-02-11 | 2005-08-25 | The University Of York | Induction of apoptosis by inhibition of sirtuin sirt1 expression |
WO2006120682A2 (en) | 2005-05-10 | 2006-11-16 | Dermipsor Ltd. | Compositions and methods for treating hyperproliferative epidermal diseases |
EP1879449A2 (en) * | 2005-05-10 | 2008-01-23 | Dermipsor Ltd | Compositions and methods for skin care |
AU2003242965B2 (en) * | 2002-07-11 | 2009-02-05 | Dermipsor Ltd. | Composition and methods for the treatment of skin disorders |
US20090098065A1 (en) * | 2000-01-11 | 2009-04-16 | Avikam Harel | Composition and methods for the treatment of skin disorders |
EP2068884A2 (en) * | 2006-10-06 | 2009-06-17 | Universitetet I Oslo | Hydroxycholesterols and its prodrugs for the treatment of insulin resistance and disorders associated therewith |
US8084049B2 (en) | 2002-06-20 | 2011-12-27 | Astion Dermatology A/S | Complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives |
WO2016178949A1 (en) * | 2015-05-01 | 2016-11-10 | The Procter & Gamble Company | Method of improving skin health and compositions therefor |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7297480B2 (en) * | 2001-06-28 | 2007-11-20 | Dermtech International | Method for detection of melanoma |
US7666451B2 (en) | 2003-03-21 | 2010-02-23 | Elizabeth Anne Mazzio | Method of treating dyshidrosis(pompholyx) and related dry skin disorders |
US7357950B2 (en) | 2003-03-21 | 2008-04-15 | Elizabeth Anne Mazzio | Topical treatment for dyshidrosis (pompholyx) and dry skin disorders |
US7183057B2 (en) * | 2004-03-31 | 2007-02-27 | Dermtech International | Tape stripping methods for analysis of skin disease and pathological skin state |
US20070183995A1 (en) * | 2006-02-09 | 2007-08-09 | Conopco, Inc., D/B/A Unilever | Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same |
US20080173558A1 (en) * | 2007-01-22 | 2008-07-24 | Contelanea Arvanitis | Fragrance-emanating nasal mask device and method |
US20080274908A1 (en) * | 2007-05-04 | 2008-11-06 | Dermtech International | Diagnosis of melanoma by nucleic acid analysis |
CN102089444A (en) | 2008-05-14 | 2011-06-08 | 德玛泰克国际公司 | Diagnosis of melanoma and solar lentigo by nucleic acid analysis |
JP2012501183A (en) * | 2008-08-28 | 2012-01-19 | ダームテック インターナショナル | How to determine the age range of skin samples |
WO2017004102A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container |
CN108430449B (en) | 2016-01-11 | 2023-01-24 | 宝洁公司 | Methods of treating skin conditions and compositions therefor |
CN114788791A (en) | 2017-06-23 | 2022-07-26 | 宝洁公司 | Compositions and methods for improving the appearance of skin |
EP3752645A4 (en) | 2018-02-14 | 2022-04-13 | Dermtech, Inc. | Novel gene classifiers and uses thereof in non-melanoma skin cancers |
KR102069088B1 (en) * | 2018-04-02 | 2020-01-22 | 양미경 | Pharmaceutical or cosmetic composition for preventing or treating hair loss or stimulating hair growth |
CA3102288A1 (en) | 2018-07-03 | 2020-01-09 | The Procter & Gamble Company | Method of treating a skin condition |
CA3134936A1 (en) | 2019-03-26 | 2020-10-01 | Dermtech, Inc. | Novel gene classifiers and uses thereof in skin cancers |
US11685766B2 (en) | 2019-05-08 | 2023-06-27 | Creighton University | 14-3-3 targeting peptides for cancer treatment |
US11518784B2 (en) | 2019-05-08 | 2022-12-06 | Creighton University | 14-3-3 targeting peptides for cancer treatment |
EP4157206A1 (en) | 2020-06-01 | 2023-04-05 | The Procter & Gamble Company | Method of improving penetration of a vitamin b3 compound into skin |
US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0052705A1 (en) * | 1980-11-24 | 1982-06-02 | Joel E. Bernstein, M.D. | Composition for treating acne vulgaris |
DE4335454A1 (en) * | 1993-10-19 | 1995-04-20 | Schleicher Peter | Geriatric medical composition |
WO1998052529A1 (en) * | 1997-05-23 | 1998-11-26 | The Procter & Gamble Company | Skin care compositions comprising vitamin b3 and a skin conditioning component |
DE29916231U1 (en) * | 1999-09-15 | 2000-02-17 | Renner Jobst | Multivitamin and mineral preparation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4067975A (en) * | 1975-08-04 | 1978-01-10 | Yu Ruey J | Treatment of psoriasis with 6-aminonicotinamide and thionicotinamide |
HU209067B (en) * | 1991-12-30 | 1994-03-28 | Tatar | Process for the production of hair-fall moderating preparation |
US6429218B1 (en) * | 1997-05-19 | 2002-08-06 | Joseph Scivoletto | Method of controlling niacin concentration in lotion |
US6248763B1 (en) * | 1998-05-19 | 2001-06-19 | Scivoletto Rosemarie | Composition for treating skin conditions |
US6107349A (en) * | 1998-04-16 | 2000-08-22 | Mantynen; Philip R. | Method and composition for treating psoriasis |
-
2000
- 2000-01-11 IL IL133976A patent/IL133976A/en not_active IP Right Cessation
-
2001
- 2001-01-09 IL IL15070601A patent/IL150706A0/en unknown
- 2001-01-09 DK DK01900231T patent/DK1259240T3/en active
- 2001-01-09 AU AU23929/01A patent/AU782558B2/en not_active Ceased
- 2001-01-09 CA CA2396186A patent/CA2396186C/en not_active Expired - Fee Related
- 2001-01-09 EP EP01900231A patent/EP1259240B8/en not_active Expired - Lifetime
- 2001-01-09 DE DE60121303T patent/DE60121303T2/en not_active Expired - Lifetime
- 2001-01-09 ES ES01900231T patent/ES2267706T3/en not_active Expired - Lifetime
- 2001-01-09 WO PCT/IL2001/000017 patent/WO2001051051A2/en active IP Right Grant
- 2001-01-09 AT AT01900231T patent/ATE332136T1/en active
-
2002
- 2002-07-11 US US10/192,842 patent/US20030032617A1/en not_active Abandoned
-
2003
- 2003-05-27 HK HK03103749A patent/HK1051497A1/en not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0052705A1 (en) * | 1980-11-24 | 1982-06-02 | Joel E. Bernstein, M.D. | Composition for treating acne vulgaris |
DE4335454A1 (en) * | 1993-10-19 | 1995-04-20 | Schleicher Peter | Geriatric medical composition |
WO1998052529A1 (en) * | 1997-05-23 | 1998-11-26 | The Procter & Gamble Company | Skin care compositions comprising vitamin b3 and a skin conditioning component |
DE29916231U1 (en) * | 1999-09-15 | 2000-02-17 | Renner Jobst | Multivitamin and mineral preparation |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Derwent Publications Ltd., London, GB; AN 1994-170436 XP002183599 FORGACS ET AL: & HU 209 067 B (TATAR J), 28 March 1994 (1994-03-28) * |
MORIMOTO ET AL: "an open study of vitamin D3 treatment in psoriasis vulgaris" BRITISH JOURNAL OF DERMATOLOGY, vol. 115, 1986, pages 421-429, XP000905334 cited in the application * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090098065A1 (en) * | 2000-01-11 | 2009-04-16 | Avikam Harel | Composition and methods for the treatment of skin disorders |
US8084049B2 (en) | 2002-06-20 | 2011-12-27 | Astion Dermatology A/S | Complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives |
AU2003242965B2 (en) * | 2002-07-11 | 2009-02-05 | Dermipsor Ltd. | Composition and methods for the treatment of skin disorders |
WO2005078091A1 (en) * | 2004-02-11 | 2005-08-25 | The University Of York | Induction of apoptosis by inhibition of sirtuin sirt1 expression |
US7863436B2 (en) | 2004-02-11 | 2011-01-04 | The University Of York | Induction of apoptosis by inhibition of sirtuin SIRT1 expression |
US8034788B2 (en) | 2005-05-10 | 2011-10-11 | Dermipsor Ltd. | Composition and methods for skin care |
EP1879595A2 (en) * | 2005-05-10 | 2008-01-23 | Dermipsor Ltd | Compositions and methods for treating hyperproliferative epidermal diseases |
JP2008540513A (en) * | 2005-05-10 | 2008-11-20 | ダーミプソル リミテッド | Compositions and methods for skin care |
US9603861B2 (en) | 2005-05-10 | 2017-03-28 | Dermipsor Ltd. | Compositions and methods for treating hyperproliferative epidermal diseases |
EP1879595A4 (en) * | 2005-05-10 | 2009-07-15 | Dermipsor Ltd | Compositions and methods for treating hyperproliferative epidermal diseases |
EP1879449A4 (en) * | 2005-05-10 | 2009-12-16 | Dermipsor Ltd | Compositions and methods for skin care |
EP1879449A2 (en) * | 2005-05-10 | 2008-01-23 | Dermipsor Ltd | Compositions and methods for skin care |
JP2008540514A (en) * | 2005-05-10 | 2008-11-20 | ダーミプソル リミテッド | Compositions and methods for the treatment of hyperproliferative epidermal diseases |
WO2006120682A2 (en) | 2005-05-10 | 2006-11-16 | Dermipsor Ltd. | Compositions and methods for treating hyperproliferative epidermal diseases |
AU2006245283B2 (en) * | 2005-05-10 | 2012-11-01 | Dermipsor Ltd. | Compositions and methods for treating hyperproliferative epidermal diseases |
CN101193641B (en) * | 2005-05-10 | 2013-05-29 | 德米普瑟尔有限公司 | Compositions and methods for treating hyperproliferative epidermal diseases |
US9173835B2 (en) | 2005-05-10 | 2015-11-03 | Dermipsor Ltd. | Compositions and methods for treating hyperproliferative epidermal diseases |
EP2068884A2 (en) * | 2006-10-06 | 2009-06-17 | Universitetet I Oslo | Hydroxycholesterols and its prodrugs for the treatment of insulin resistance and disorders associated therewith |
WO2016178949A1 (en) * | 2015-05-01 | 2016-11-10 | The Procter & Gamble Company | Method of improving skin health and compositions therefor |
Also Published As
Publication number | Publication date |
---|---|
IL133976A0 (en) | 2001-04-30 |
ATE332136T1 (en) | 2006-07-15 |
IL150706A0 (en) | 2003-02-12 |
EP1259240B1 (en) | 2006-07-05 |
EP1259240A2 (en) | 2002-11-27 |
WO2001051051B1 (en) | 2002-09-26 |
CA2396186C (en) | 2011-03-22 |
IL133976A (en) | 2006-09-05 |
DE60121303D1 (en) | 2006-08-17 |
DK1259240T3 (en) | 2006-10-30 |
HK1051497A1 (en) | 2003-08-08 |
CA2396186A1 (en) | 2001-07-19 |
AU2392901A (en) | 2001-07-24 |
ES2267706T3 (en) | 2007-03-16 |
AU782558B2 (en) | 2005-08-11 |
US20030032617A1 (en) | 2003-02-13 |
WO2001051051A3 (en) | 2002-06-27 |
EP1259240B8 (en) | 2007-05-09 |
DE60121303T2 (en) | 2007-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1259240B1 (en) | Agents, such as nicotinamide or cadpr for the treatment of skin disorders | |
Eichelbaum et al. | Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses | |
DE69434211T2 (en) | PHENYLACETATE AND DERIVATIVES, ALONE OR IN COMBINATION WITH OTHER COMPOUNDS, FOR THE TREATMENT OF NEOPLASTIC AND OTHER DISEASES | |
DK175582B1 (en) | Use of a 17-ketosteroid compound for use in prophylaxis and treatment of retroviral infection | |
Ramstedt et al. | Action of novel eicosanoids lipoxin A and B on human natural killer cell cytotoxicity: effects on intracellular cAMP and target cell binding. | |
EP1244460B1 (en) | Use of dipyridinium compounds for treating a disease characterized by proliferating cells containing nitric oxide synthase | |
EP2305224B1 (en) | Vitamin K analog for treatment of skin or mucosal ulceration | |
EP3288531B1 (en) | Method of improving skin health and compositions therefor | |
JP2009132739A (en) | Use of at least one of cosmetically acceptable saponin or sapogenol as cosmetic agent for increasing amount of collagen iv in the dermal-epidermal junction | |
US9144560B2 (en) | Composition comprising rutin and polyunsaturated fatty acid having an inhibitory activity on 5 α-reductase | |
PL196079B1 (en) | Cosmetic composition | |
Buttke et al. | Inhibition by ketoconazole of mitogen-induced DNA synthesis and cholesterol biosynthesis in lymphocytes | |
Kang et al. | Enhancement of 1α, 25‐dihydroxyvitamin D3‐induced differentiation of human leukaemia HL‐60 cells into monocytes by parthenolide via inhibition of NF‐κB activity | |
CN100579521C (en) | Fatty acid analogues for the treatment of proliferative skin disorders | |
AU2003242965B2 (en) | Composition and methods for the treatment of skin disorders | |
US20160220589A1 (en) | Compositions and methods for the treatment of skin disorders | |
Danelli et al. | Leishmanicidal effect of LLD-3 (1), a nor-triterpene isolated from Lophanthera lactescens | |
Taoka et al. | Induction of differentiation of HL-60 cells by protein kinase C inhibitor, K252a | |
Hidaka et al. | The effect of α-(3, 5-di-t-butyl-4-hydroxybenzylidene)-γ-butyrolactone (KME-4), a new anti-inflammatory drug, on leucocyte migration in rat carrageenan pleurisy | |
IL150706A (en) | Combinations of nicotinamide and vitamin d agents and use thereof in preparation of compositions for the treatment of skin disorders | |
US5618545A (en) | Skin-cosmetic composition | |
US20160310460A1 (en) | Itch suppression by fucoxanthin | |
WO2022045385A1 (en) | Composition for preventing hair loss or promoting hair regrowth | |
WO2023175136A1 (en) | Combination of dasatinib and lovastatin for use in methods for the treatment of cardiac fibrosis | |
CN116350531A (en) | Anti-glycation application of opal D |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2396186 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 23929/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 150706 Country of ref document: IL Ref document number: 10192842 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001900231 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWP | Wipo information: published in national office |
Ref document number: 2001900231 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 23929/01 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001900231 Country of ref document: EP |